Low Dose Paclitaxel and Carboplatin for Ovarian Cancer
Author Information
Author(s): Rohini Sharma, Janet Graham, Sarah Blagden, Hani Gabra
Primary Institution: Imperial College, London, UK
Hypothesis
The platelet sparing effect of paclitaxel occurs at doses lower than that required for response.
Conclusion
The addition of low dose paclitaxel allows delivery of weekly dose dense carboplatin AUC 3 by maintaining platelet counts without compromising dose dense carboplatin mediated tumour response.
Supporting Evidence
- The study demonstrated that low dose paclitaxel does not worsen neuropathic symptoms.
- Patients maintained platelet counts while receiving dose dense carboplatin.
- The regimen was well tolerated and effective in a poor prognostic group.
Takeaway
This study shows that giving a small amount of paclitaxel can help patients with ovarian cancer get more effective treatment without causing low platelet counts.
Methodology
Seven patients with platinum resistant ovarian cancer were treated with carboplatin AUC 3 and low dose paclitaxel 20 mg/m2.
Limitations
The study has a small sample size with only seven patients.
Participant Demographics
All participants had platinum resistant epithelial ovarian cancer and grade ≥ 2 neuropathic symptoms.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website